Worldwide experience: comparison of this study to 2 previously reported series
| . | Country . | ||
|---|---|---|---|
| . | Belgium . | United States . | France . |
| Study authors | Vermylen et al21 | Walters et al19,24 | Current study |
| Period | 04/86–01/97 | 09/91–03/99 | 11/88–12/04 |
| No. of patients | 50 | 50 | 87 |
| Median age, y (range) | 7.7 (0.9–23) | 9.9 (3.3–14) | 8.8 (2.2–22) |
| No. of strokes (%) | 4 (8) | 14/26 (54) | 36 (41) |
| Mean ferritin level, ng/mL (range) | ? | 1542 (58–6795) | 911 (13–3820) |
| ATG source | Fresenius | Horse ATGAM | Rabbit ATG |
| ATG dose | 15–90 mg/kg | 90 mg/kg | 20 mg/kg |
| Follow-up | |||
| Median, y (range) | 5 (0.9–15) | 3.3 (0.5–7.9) | 6 (2–17.9) |
| More than 2 y | — | 26 | 87 |
| Rejections, % | 10 | 10 | 7 |
| TRM, % | 7 | 6 | 6.9 |
| EFS, % | 82 | 84 | 86.1 |
| aGvHD above grade II | 20 | 15 | 20 |
| cGvHD | 20 | 12 | 13.5 |
| . | Country . | ||
|---|---|---|---|
| . | Belgium . | United States . | France . |
| Study authors | Vermylen et al21 | Walters et al19,24 | Current study |
| Period | 04/86–01/97 | 09/91–03/99 | 11/88–12/04 |
| No. of patients | 50 | 50 | 87 |
| Median age, y (range) | 7.7 (0.9–23) | 9.9 (3.3–14) | 8.8 (2.2–22) |
| No. of strokes (%) | 4 (8) | 14/26 (54) | 36 (41) |
| Mean ferritin level, ng/mL (range) | ? | 1542 (58–6795) | 911 (13–3820) |
| ATG source | Fresenius | Horse ATGAM | Rabbit ATG |
| ATG dose | 15–90 mg/kg | 90 mg/kg | 20 mg/kg |
| Follow-up | |||
| Median, y (range) | 5 (0.9–15) | 3.3 (0.5–7.9) | 6 (2–17.9) |
| More than 2 y | — | 26 | 87 |
| Rejections, % | 10 | 10 | 7 |
| TRM, % | 7 | 6 | 6.9 |
| EFS, % | 82 | 84 | 86.1 |
| aGvHD above grade II | 20 | 15 | 20 |
| cGvHD | 20 | 12 | 13.5 |
— indicates not available, ?, unknown.